CSL

Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL
Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL
BioPharma Dive
clinical trials
plasma
COVID-19
Takeda
CSL
Flag link:
UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B
UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B
Seeking Alpha
uniQure
CSL
hemophilia B
etranacogene dezaparvovec
Flag link:
Takeda, CSL forge coronavirus alliance, forgoing their own drugs in the process
Takeda, CSL forge coronavirus alliance, forgoing their own drugs in the process
BioPharma Dive
Takeda
CSL
COVID-19
plasma
drug development
Flag link:
Want to win over payers, pharma? Forget the 'me-too' drugs, CSL chief says
Want to win over payers, pharma? Forget the 'me-too' drugs, CSL chief says
Fierce Pharma
CSL
Paul Perreault
me-too drugs
payers
Flag link:
Shire scores new FDA thumbs-up for HAE drug Cinryze in latest bid to fend off rival CSL
Shire scores new FDA thumbs-up for HAE drug Cinryze in latest bid to fend off rival CSL
Fierce Pharma
CSL
HAE
Shire
Cinryze
Haegarda
Flag link:
CSL revamps branding to recruit employees, partners
CSL revamps branding to recruit employees, partners
Fierce Pharma
CSL
branding
Flag link:
CSL snags a preclinical stem cell therapy in $416M Calimmune buyout
CSL snags a preclinical stem cell therapy in $416M Calimmune buyout
Endpoints
CSL
Calimmune
M&A
stem cells
Flag link:
FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire
FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire
Endpoints
FDA
CSL
HAE
hereditary angiodema
Shire
Haegarda
Firazyr
Kalbito
Flag link:
Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch
Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch
Fierce Pharma
Shire
rare disease
CSL
patents
Haegarda
HAE
hereditary angiodema
Flag link:
Hemophilia marketing tactics raise questions as market heats up
Hemophilia marketing tactics raise questions as market heats up
Fierce Pharma
hemophilia
drug marketing
Biogen
CSL
Bayer
Roche
Flag link:
First flu vaccine with immune-boosting adjuvant approved for US market
First flu vaccine with immune-boosting adjuvant approved for US market
Stat
flu vaccines
vaccines
immune-boosting adjuvants
Fluad
CSL
Novartis
Seqirus
Flag link:
How Does Novavax Compare to Its Competitors?
How Does Novavax Compare to Its Competitors?
Yahoo/Market Realist
Novavax
Inovio
iBio
CSL
Sinovac
Biota
Flag link:
Novartis jettisons flu vaccine
Novartis jettisons flu vaccine
Seeking Alpha
Novartis
flu vaccine
vaccines
CSL
Flag link:
CSL’s potential new treatment for heart disease could boost profits further
CSL’s potential new treatment for heart disease could boost profits further
Motley Fool
CSL
Flag link:
Cholesterol Drug From Trash Seen Preventing Heart Attack
Cholesterol Drug From Trash Seen Preventing Heart Attack
Bloomberg
cholesterol
hemophilia
heart attack
CSL
Flag link:
CSL Pays $64M To Settle Antitrust Suit Over Plasma Pricing
CSL Pays $64M To Settle Antitrust Suit Over Plasma Pricing
Pharmalot
CSL
plasma-based pharmaceuticals
antitrust
Flag link:
An Interesting Bio Play in the Blood Disorder Niche
An Interesting Bio Play in the Blood Disorder Niche
Motley Fool
hereditary angiodema
Dyax
Shire
CSL
ViroPharma
Biovitrum
Halozyme
Cinryze
Flag link:
CSL Reviews Non-Plasma Unit as Perreault Mulls Options
CSL Reviews Non-Plasma Unit as Perreault Mulls Options
Bloomberg
CSL
bioCSL
Flag link:
CSL First-Half Profit Jumps on Blood-Based Therapies
CSL First-Half Profit Jumps on Blood-Based Therapies
Bloomberg
CSL
earnings
Flag link:
Convulsion Risk From CSL Flu Vaccine Linked To Components
Convulsion Risk From CSL Flu Vaccine Linked To Components
Bloomberg
CSL
vaccines
Flu
Flag link:

Pages